(Q30450875)

21 June 2017

title

Medical management of Crohn's disease: current therapy and recent advances (English)

1 reference

21 June 2017

0 references

Brian W Behm

1

1 reference

21 June 2017

Stephen J Bickston

series ordinal

2

1 reference

21 June 2017

publication date

1 January 2006

1 reference

Expert Review of Clinical Immunology

21 June 2017

published in

1 reference

21 June 2017

volume

2

1 reference

21 June 2017

issue

1

1 reference

21 June 2017

page(s)

109-120

1 reference

Molecular mechanisms of sulfasalazine-induced T-cell apoptosis

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Sulfasalazine. Adverse effects and desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

The effectiveness of budesonide therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

A controlled double blind study of azathioprine in the management of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Azathioprine induced nodular regenerative hyperplasia in IBD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Extracolonic malignancies in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Cancer in patients with ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

The relationship between infliximab treatment and lymphoma in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Double blind, placebo controlled trial of metronidazole in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Preliminary study of ciprofloxacin in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

An open-label evaluation of rifaximin in the treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Lactobacillus GG in inducing and maintaining remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Predictive Factors of Response of Perianal Crohn's Disease to Azathioprine or 6-Mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Fistula response to methotrexate in Crohn's disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Sargramostim for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Anti-interleukin-12 antibody for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Hyperbaric oxygenation in severe perineal Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.1.109

21 January 2018

Identifiers

DOI

10.1586/1744666X.2.1.109

1 reference

21 June 2017

1 reference